Drug Profile
Research programme: immunological disorders therapy - Immune Control/Provid Pharmaceuticals
Latest Information Update: 04 Apr 2008
Price :
$50
*
At a glance
- Originator Immune Control; Provid Pharmaceuticals
- Class
- Mechanism of Action Serotonin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 06 Jul 2005 Early research in Immunological disorders in USA (unspecified route)